Adamant Biomedical Investments' main business, which presented itself to the media on June 20, 2001, is institutional and private asset management in the area of Biomedicine. The novel "Diamond" concept combines investments in Biotechnology, Medical Technology and Specialty Pharmaceuticals. This allows participation in the strongly performing biomedical sector while at the same time minimizing the volatility typical for biotechnology. Adamant's management team and investment board is composed of experts with ample experience in both Healthcare and Finance sectors.
The biomedical sector provides a particularly impressive potential for growth and business success for at least the next ten years: novel drugs and therapeutic innnovations will radically change the face of current medicine in lockstep with concepts of health and illness.
Adamant Biomedical Investments AG was founded in December 2000 as a Joint Venture between Swiss Life Asset Management (51%) and three former Bellevue Group partners, i.e. Dr. Nora Frey, Dr. Philipp Mekler and Dr. Cyrill Zimmermann. Adamants board is chaired by Dominique P. Morax, CFO Rentenanstalt/Swiss Life. Adamant has been operational since January 2, 2001 and manages both the SL Fund-Equity Biomedical and direct mandates.
Phone +41 61 275 92 11
Phone +41 61 275 92 16